UNSPSC 51285203: Trimethoprim

This classification denotes a urinary anti-infective agent with the molecular formula C14H18N4O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier AN164J8Y0X, chemically known as 2,4-pyrimidinediamine, 5-((3,4,5-trimethoxyphenyl)methyl)- but more generally known as trimethoprim, which bears U.S. National Institutes of Health Compound Identifier 5578. The European Medicines Agency schedules Trimethoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11310MIG.

UNSPSC 51285203 Trimethoprim is a Commodity code that classifies individual pharmaceutical products for procurement by state and local health agencies. Recent state and local opportunities show little activity directly under this code; the two most recent records tagged to it involve a completed piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium and a naloxone and drug deactivation systems procurement, neither of which centers on trimethoprim or closely related antibiotics. When state and local health departments and special-purpose health districts do procure individual pharmaceuticals under commodity codes in this family, they typically source through cooperative purchasing vehicles such as MMCAP or established prime vendor relationships, often bundling multiple drug products in a single contract award rather than issuing separate solicitations for individual active ingredients.

The Illinois Department of Public Health awarded a piggyback pharmaceutical contract to Chartwell Rx LLC on August 28, 2026, for doxycycline and ciprofloxacin tablets through MMCAP Infuse with a total value of $2,999,999.11 over three years; Seminole County, Florida issued an IFB on June 30, 2026, for naloxone and drug deactivation systems with quarterly deliveries. Recent activity under the code is geographically sparse, with the two records spanning Illinois and Florida. State and local pharmaceutical procurement at the commodity level typically flows through established group purchasing vehicles rather than open market RFPs or IFBs, making direct solicitation activity under individual drug codes infrequent compared to broader pharmaceutical family codes.